31.05.2013 - Genmab's and GSK's CD20 antibody ofatumumab challenges Roches
glyco-optimised obinutuzumab as treatment for CCL patients.
According to data presented by the Danish-British partnership, a combination therapy of ofatuzumab (Arzerra) and chlorambucil significantly improved median progression-free survival of patients with chronic lymphocytic leukaemia (CLL). Patients treated with the combination lived 22.4 months on average without the disease worsening. That is 9.3 months more than in patients receiving the chemotherapeutic alone (13.1 months; Hazard Ratio 0.57; p<0.001).
Two weeks prior to that, Roche had also met the primary endpoint of a Phase III study demonstrating a 12 months PFS benefit (23 months vs 10.9 months, HR=0.14, 95% CI 0.09-0.21, p <.0001) of a combination of obinutuzumab + chlorambucil compared to chemotherapy alone.
According to Genmab, serious adverse events were in the expected range with 3% of serious infusion reactions. Although not being statistically significant at this point in time, Roche published data indicating a higher rate of first-contact infusion reactions than observed after injections of the company's blockbuster rituximab.CLL is the most common form of leukaemia in adults. At present, no curative therapy is available.
29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.
27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).
21.04.2016 An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.
21.04.2016 For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.
19.04.2016 British drug developer Heptares Therapeutics and mAb maker Kymab Ltd have partnered up in yet another immuno-oncology collaboration. The companies plan to discover antibody meds targeting a superfamily of receptors.
15.04.2016 Not every company is put off by the current stock market climate. Swiss biopharma company GeNeuro has gone public at Euronext Paris, raising €33m in the process. Others, meanwhile, have to find different ways to raise money.
13.04.2016 Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new numbers were presented at the annual Swiss Biotech Day – which set new records as well.
12.04.2016 German-Dutch life science investment specialist Forbion Capital Partners has raised more than €180m for its venture capital fund Forbion Capital Fund III. Once more the money will primarily go to European start-ups.
08.04.2016 Do you win by being innovative?, was the question asked at this year’s DIA Euromeeting in Hamburg. In a relaxed and cooperative atmosphere, regulators, physicians and patients had ample opportunity to interact with the healthcare industry.